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Abstract 
Background. Effects of single ascending doses of MDCO-216 on plasma lipid and lipoprotein 
levels were assessed in human healthy volunteers and in patients with stable coronary artery 
disease (CAD).  
Methods. MDCO-216 was infused at a single dose of 5, 10, 20, 30 or 40 mg/kg over 2h and 
blood was collected at 2, 4, 8, 24, 48, 168 and 720 h after start of infusion (ASOI). 
Lipoprotein lipids were assessed by FLPC and by 1H-NMR. 
Results. Plasma concentrations of free cholesterol (FC) displayed a rapid and dose-
dependent rise peaking at 8 h but remaining above baseline until 48 h ASOI, whereas levels 
of esterified cholesterol (CE) increased at lower doses but not at higher doses, and even 
decreased below baseline at the highest dose. Plasma cholesterol esterification rate (CER) 
decreased with a first nadir between 4 and 8 h and a second nadir at 48 h ASOI. Taken over 
all subjects receiving MDCO-216 the increase in FC at 8 h correlated inversely with the drop 
in CER at 4 h but positively with the increase in basal and SR-BI-mediated cholesterol efflux 
capacities at 2 h ASOI.  
Upon FPLC analysis FC was found to increase first in HDL and VLDL and later (at 48 or 168 h 
ASOI) in LDL. CE initially decreased in LDL and HDL but after 24 h started to increase in VLDL 
and LDL whereas HDL-CE was still below baseline at 48 h.  PL showed the same pattern as FC. 
TG also rose rapidly, most prominently in VLDL, but also in LDL and HDL. Apo-E in VLDL 
increased at 4-8 h but returned to baseline at 24 h ASOI.  
1H-NMR analysis showed a rapid and dose-dependent increase in HDL particle size, peaking 
at 2 h and returning to baseline at 24h, and a small increase in HDL particle concentration. 
After infusion of the 40 mg/kg dose LDL and VLDL-particles also increased in number and 
size.  
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Conclusion: a single administration of MDCO-216 caused rapid changes in lipid levels and 
lipoprotein composition, some of which persisted for at least 7 days. 
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INTRODUCTION 
Intravenous infusion of various apoA-I -phospholipid complexes (“reconstituted HDL”, rec-
HDL) has been under investigation since the mid-1990ties as an approach to reduce 
atherosclerotic plaque burden (reviewed in 1).  
Based on the observation that carriers of the apolipoprotein A-I Milano (apoA-IM) variant 
have a reduced incidence of atherosclerosis and cardiovascular events (reviewed in 2) rec-
HDL containing apoA-IM has been developed and was shown to reduce plaque burden in 
several animal studies (3-7).  More than 10 years ago repeated infusion of rec-HDL 
containing apoA-IM (at the time named ETC-216) was shown to cause rapid regression of 
atherosclerotic plaque burden in patients with acute coronary syndromes, as measured by 
intravascular ultrasound (8). More recently the same product manufactured by an improved 
process, called MDCO-216, was shown by us to be safe in a multiple ascending dose toxicity 
study in cynomolgus monkeys (9). This study also demonstrated strongly elevated free 
cholesterol (FC) levels and enhanced ABCA1-mediated cholesterol efflux capacity of serum 
after drug infusion, accompanied by a shift of apoE from HDL toward VLDL and LDL (9). 
Most recently we assessed the safety and pharmacodynamics of single ascending doses of 
MDCO-216 in healthy volunteers and in patients with stable coronary artery disease (CAD). 
We recently reported time- and dose-dependent changes in plasma lipids, apolipoproteins 
and serum cholesterol efflux capacities (10). Somewhat surprisingly we found only minimal 
changes in total plasma cholesterol (10). Other groups infusing other rec-HDL products in 
humans have described strong increases in plasma cholesterol after infusion of CER-001 (11) 
or CSL-112 (12), initially in the form of a rise in FC in HDL. The goal of the present paper was 
therefore to assess the effects of MDCO-216 on levels of FC, esterified cholesterol (CE) and 
other lipids in total plasma and in individual lipoproteins HDL, LDL and VLDL.  We found that 
6 
 
MDCO-216 causes rapid and sustained dose-dependent increase of plasma FC, first within 
HDL and VLDL and later in LDL.  At the highest dose HDL-CE was decreased for at least 48 h, 
while VLDL-and LDL-CE increased. The initial increase in FC correlated with the rise in basal 
or SRB1-mediated cholesterol efflux capacity and inversely with the drop in endogenous 
cholesterol esterification rate.  
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MATERIALS AND METHODS 
 
Drug Product 
MDCO-216 is a complex of highly purified dimeric recombinant apoA-IM and palmitoyl-
oleoyl-phosphatidylcholine (POPC).  Complexation with POPC was performed using a high-
pressure homogenization procedure. The final product contained 13 mg/ml protein, 14 
mg/ml POPC, 1.3 mg/ml di-sodium hydrogen phosphate heptahydrate, 0.178 mg/ml sodium 
dihydrogen phosphate dehydrate, 62 mg/ml sucrose, 8.2 mg/ml mannitol. Physicochemical 
properties of the complex were described in detail before (9) and its concentration is 
expressed as protein content. 
 
Study Design 
The study design and protocol were described in detail before (10). Briefly, the study 
protocol was developed by the Sponsor, The Medicines Company, and organized and 
executed by the Centre for Human Drug Research (CHDR) in Leiden, Netherlands, in 
compliance with the Declaration of Helsinki. The protocol was approved by accredited local 
(BEBO, Assen, The Netherlands) and national (CCMO, The Hague, The Netherlands) 
independent medical ethics committees. After signing informed consent and meeting all 
inclusion and exclusion criteria, 24 healthy volunteers and 24 patients with stable CAD were 
randomized between February and October 2013 and received a two hour infusion of 
MDCO-216 or placebo.  
 
Concomitant treatment 
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Subjects were excluded from the trial if there was a recent or current history of 
investigational drug products. Stable CAD patents were allowed to remain on all current 
medications, including those for hypercholesterolemia, hypertension and diabetes. 
Drug administration, randomization  
After overnight fasting healthy volunteers received single doses of 5, 10, 20, 30 or 40 mg 
(based on protein)kg and stable CAD patients received doses of 10, 20, 30 or 40 mg (based 
on protein)/kg. Subjects were assigned in a 2:1 ratio to MDCO-216 or matching placebo to 
maintain blinding. Dose escalation was only permitted after approval from a Safety Review 
Committee consisting of specialists in Cardiology, Vascular Medicine, the Principal 
Investigator and Medical Director from the sponsor following the review of safety data to 
day 7. In the first two cohorts of healthy volunteers (5 mg/kg and 10 mg/kg) 2 subjects 
received MDCO-216 and 1 subject received placebo. In the remaining cohorts of both 
healthy volunteers and CAD patients 4 subjects received MDCO-216 and 2 received placebo. 
Altogether, therefore, 8 healthy volunteers and 8 CAD patients received placebo. 
 
Laboratory analyses 
Plasma levels of free and esterified cholesterol, of cholesterol esterification rate (CER) and of 
lipoprotein lipids and apolipoproteins after separation by FPLC were measured using 
methods described in detail before (9). In the healthy volunteers only the 20 mg/kg and 40 
mg/kg dose groups were analyzed, while in the CAD patients all 4 dose groups except 
placebo were analyzed. For the 10, 20 and 30 mg/kg doses only the 0 h, 4 or 8 h and 24 h 
time points were analyzed, while for the 40 mg/kg dose the 48 h and 168 h time points were 
also assessed. After FPLC separation total cholesterol (TC), free cholesterol (FC), triglycerides 
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(TG) and phospholipids (PL) were measured in the 30 fractions eluted from the column. 
Esterified cholesterol (CE) was calculated as TC minus FC.  
For CER, which estimates the ability of LCAT to esterify cholesterol within endogenous 
lipoproteins, FC was measured in plasma samples before and after 1h incubation at 37°C by 
a standard enzymatic assay. Reaction was stopped by adding 0.15 mol/L sodium iodoacetate 
as LCAT inhibitor. Results are expressed as nmoles of esterified cholesterol generated. 
Basal and ABCA1-mediated cholesterol efflux capacities in control or cAMP-pretreated J774 
cells, SR-BI-mediated cholesterol efflux from Fu5AH cells and ABCG-1 mediated efflux from 
transfected BHK cells were determined as described in the previous paper (10). 
Lipoprotein particle concentrations and sizes were assessed by NMR LipoProfile® analysis at 
LipoScience (now LabCorp), Raleigh, NC, as described before (14). Particle concentrations 
and mean sizes are reported for HDL (diameter between 7.3 and 14 nm), LDL plus IDL 
(diameter between 18-29 nm) and VLDL plus chylomicrons (diameter above 29 nm). 
Results are presented as means and SEM according to dose and time after start of infusion.  
For each subject and measured parameter the delta (value at time point x – value at baseline 
just prior to start of infusion) was calculated. Student t-test for paired observations was done 
within each dose group to see if a mean value at t=x significantly differed from baseline value 
of that dose group. Student t-test for unpaired observations was performed to see whether a 
mean delta in a drug-treated group for a given time point differed significantly from the mean 
delta in the placebo-treated subjects for that time point. P values <0.05 were considered 
statistically significant. 
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RESULTS  
Effects on plasma free cholesterol, esterified cholesterol and cholesterol esterification rate 
Plasma levels of FC remained stable over time in the subjects receiving placebo and 
increased  in those receiving MDCO-216 reaching peak at 8 h with a second peak at 48 h in 
CAD patients. In healthy volunteers these increases were significant at doses >= 20 mg/kg 
while in CAD patients the increase was significant at all doses as compared to baseline and 
placebo (Fig. 1 top panels).   As shown in Data Supplement Fig. I the effect on FC was not 
dose-linear: the amount of FC increase at 8 h was small at lower doses but at doses >= 30 
mg/kg the rise was stronger and in CAD patients more pronounced than in healthy subjects. 
In contrast CE levels did not clearly increase (as compared to placebo values which tended to 
rise over time), and after the 40 mg/kg dose CE levels were even below placebo at 24 and 48 
h after infusion (Fig. 1 bottom panels). 
To determine whether the increase in FC could be attributed to a decreased LCAT activity we 
determined the endogenous plasma CER before and after infusion of MDCO-216. As shown 
in Fig. 2 infusion of MDCO-216 caused a time and dose-dependent decrease in CER in both 
healthy volunteers and patients, with the first drop between 2 and 8 h, the second at 48 h 
after start of infusion.  As shown in Fig. 3 (A), the increase in FC at 8 h was significantly 
inversely correlated with the decrease in CER at 4 h (r= -0.43, p =0.03).  
Since this correlation was not very strong we explored whether the increase in FC could also 
be related to the changes in cholesterol efflux capacities described in our previous paper 
(10). We found that delta FC at 8 h correlated strongly and positively with the increase of 
basal (Fig. 3B) and SR-BI-mediated (Fig. 3C) efflux capacities at 2 h (r = 0.74 and 0.76 
respectively, p<0.001), but not significantly with the increase of ABCA1-mediated efflux at 2 
h (r=0.36, p=0.15), nor with the increase in ABCG1-mediated efflux at 2 h (r=0.27, p=0.19).  
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Thus, the increase of plasma FC is mainly the result of MDCO-216-induced increase of SR-BI-
mediated cholesterol efflux with a minor contribution of a decrease of CER. 
 
Effects on the composition of lipoprotein fractions isolated by FPLC 
Complete results of the FPLC analyses are provided in Supplementary Tables II and III for the 
healthy volunteers and CAD patients, respectively. The changes in lipoprotein lipids induced 
by the 40 mg/kg dose are depicted in detail in Fig. 4.  There was an early increase in HDL-PL 
likely reflecting the POPC infused as constituent of MDCO-216, accompanied by a parallel 
rise in HDL-FC. These lipids rapidly left the HDL region, and then increased in the VLDL and 
thereafter in the LDL fraction, where they were still significantly above baseline at 2 or 7 
days after infusion. CE in HDL decreased below baseline whereas CE in VLDL and later in LDL 
rose above baseline.  
We showed before (10) that MDCO-216 infusion caused a rapid and considerable increase in 
total plasma TG; here we report that this increase occurs in all three lipoprotein fractions, 
although most pronounced in VLDL. Effects on TG were more marked in CAD patients than in 
healthy volunteers in all lipoprotein fractions. 
Plasma apoC-III levels showed changes over time after MDCO-216 infusion but these were 
not significantly different from those of placebo-treated subjects at all time-points (Data 
Supplement Figure II). 
Changes in plasma levels of apoA-I (total and apoA-IMilano), apoB and apoE were reported 
before (10, 16). The distribution of apoA-I, apoA-I Milano and apoE over lipoproteins was 
determined by Western blotting after FPLC separation. ApoA-I and apoA-IMilano (detected 
with the 17F3 Mab) were recovered for over 90% in the HDL fraction prior to and at all times 
after infusion of all doses (not shown). As shown in Fig. 5 apoE showed a small but significant 
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increase in the VLDL fraction at 8 h after start of infusion of MDCO-216 parallel with a 
decrease in the LDL fraction and no change in the HDL fraction.  
 
Lipoprotein particle concentrations and sizes measured by NMR 
HDL 
MDCO-216 caused an increase in HDL particle concentration between 2 and 8 h after start of 
infusion at 10 mg/kg in the healthy volunteers and at all doses in the CAD patients. At the 40 
mg/kg dose HDL particle concentration decreased below baseline at 2h and in healthy 
volunteers also at 48 h after start of infusion (Fig. 6 and Supplementary Table III). 
MDCO-216 at doses of 20, 30 and 40 mg/kg caused the HDL particle size to increase during 
the first 8 h in both groups, the increase being larger in healthy volunteers than in CAD 
patients. In the healthy volunteers receiving 20 or 30 mg/kg HDL size decreased significantly 
below baseline between 24 and 168 h after infusion (Fig. 6 and Supplementary Table III). 
 
LDL 
MDCO-216  at 40 mg/kg caused a rapid and long lasting increase in LDL particle number in 
healthy volunteers and more pronounced in CAD patients. Peak values were reached at 48 h 
in both groups. At 20 mg/kg the increases were smaller (Supplementary Table IV).  
LDL  size increased slightly after infusion of 40 mg/kg in healthy volunteers between 4 and 24 
h, but not at lower doses, while in CAD patients there was no significant changes in LDL size 
at any dose or timepoint (Supplementary Table IV). 
 
VLDL  
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VLDL particle number increased in both healthy volunteers and CAD patients at 4 and 8 h 
after infusion of the 10 and 20 mg/kg doses and also at 24 and 48 h at the 30 g/kg doses 
(Supplementary Table V). VLDL size was increased above baseline between 4 and 168 h in  
healthy volunteers after the 30 and 40 mg/kg dose.  In CAD patients VLDL size increased to a 
smaller extent and only at 4 and 8 h after infusion. Lower doses had no or little effect on 
either particle number or size (Supplementary Table V). 
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DISCUSSION 
Effects on free and esterified cholesterol; relation with CER and cholesterol efflux capacity 
Infusion of MDCO-216 caused rapid increases in plasma FC which was more pronounced and 
sustained in CAD patients. The increase in FC could in theory be the result of (i) increased 
efflux of cholesterol from tissues into plasma, (ii) hampered esterification of FC by LCAT, (iii) 
a decreased delivery from plasma to tissues, or (iiii) an increased secretion of FC as new 
lipoproteins by the liver and small intestine. The first mechanism is clearly plausible in view 
of the strong increases in serum efflux capacities as reported in the previous paper (10), and 
is actually supported by the high positive correlations between the delta FC at 8 h and the 
delta’s for basal and SR-BI-mediated efflux capacities at 2 h (Fig. 3 B and C). This relation is 
also in agreement with the finding, reported recently elsewhere (16), that infusion of MDCO-
216 leads to a prompt increase of larger (alpha-1 and alpha-2) HDL which are known to be a 
functional cholesterol acceptor via the SR-BI carrier in liver cells (17). 
The second mechanism, inhibition of cholesterol esterification, is supported by the 
temporary drop in CER with a nadir at 4 h (Fig. 2) which correlated inversely with the 
increase in FC at 8 h (Fig. 3 A). It also is consistent with decreased LCAT activity in carriers of 
the apoA-IMilano mutation reported before (15). However, the size of the CER drop (15 
nmoles/ml/h in the period between 2 and 8 h) would predict an increase of 8*15 = 120 
nmoles at 8h, much below the actually observed increase in plasma free cholesterol (800 
nmoles/ml at 8 h after start of infusion in CAD patients). It seems therefore that the increase 
in FC is mainly driven by enhanced cholesterol efflux capacity, at least during the initial 8 h. 
The third or fourth mechanism may play a role in the increased FC seen at later time points, 
which remains to be assessed in future studies.  
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In contrast to studies with CSL-112 (12) no significant increase or even a decrease in plasma 
CE occurred as compared to placebo. The reason for the drop in CE at the higher doses is 
discussed in the next section. 
Rise of FC not only in HDL but also in VLDL and LDL 
Lipoprotein separation by FPLC demonstrated that the increase in free cholesterol occurred 
not only in HDL but also in VLDL and LDL (Fig. 4, Supplementary Tables II and III). The 
appearance of FC and PL in the VLDL and LDL regions has been observed before after 
infusion of ETC-216 in rabbits (5) or monkeys (9) or of reconstituted human HDL containing 
wild-type apoA-I in mice (18). Increased amounts of FC in the VLDL region and LDL regions 
was also observed in humans receiving ETC-216 (19) or reconstituted HDL containing wild-
type apoA-I (20).  This may be attributed to relative lack of activation of LCAT by apoA-I 
Milano accompanied by formation of FC/PL rich particles containing apoE (9), as discussed in 
more detail below.  
Drop of CE in HDL and rise in LDL 
Fig. 4 also showed that the reduced plasma CE level at 24 and 48 h was the result of a drop 
in both HDL-CE and LDL-CE. Whereas the drop in HDL-CE was sustained up to 168 h after 
infusion, LDL-CE started to rise above baseline between 24 and 48 h and then remained 
elevated until 168 h. This suggests that the FC extracted from tissues was esterified by LCAT 
initially on HDL, followed by CETP-mediated transfer to VLDL and LDL in exchange for TG. 
This HDL-TG then may have been subsequently hydrolyzed by hepatic lipase.  
In line with this hypothesis the drop of HDL-CE below baseline at 24 and 48 h after the 
higher doses was accompanied by a smaller sized HDL (Fig. 6), indicating net loss of HDL core 
lipids.   
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LDL-TG showed peaks at 8 and 48 h, whereas LDL-CE initially decreased but then increased 
from 48h onwards. The pronounced increase in all LDL-lipids at 48 h in the CAD patients is in 
good agreement with the increase in LDL particle concentration observed by 1H-NMR at that 
time point, and also with the increase in LDL-cholesterol and apoB as reported in the 
previous paper (10).  
Increase in VLDL-lipids and apoE 
Increases in TG, PL and FC in VLDL were observed between 4 and 48 h after infusion of the 40 
mg/kg dose (Fig. 4).  In line with this, 1H-NMR detected prominent increases in VLDL particle 
size occurred at these time points. Whether these rises in VLDL lipids are due to decreased 
VLDL clearance or increased VLDL production is as yet unclear. Interestingly, it was recently 
shown that apoA-IMilano triggers lipolysis in primary adipose cells (21). In case this would 
have occurred in our study in vivo, it remains to be investigated whether the liberated FFA are 
directed to the liver for TG and VLDL synthesis and thereby affect VLDL levels. Another cause 
for increased VLDL production may be enhanced delivery of cholesterol from the plasma 
compartment into the liver, as observed in older studies (22).  
Alternatively, decreased VLDL clearance could have been resulted from inhibition of 
lipoprotein lipase by MDCO-216 or by an increase of apoC-III levels. Plasma apoC-III indeed 
rose to some extent at 8 h after infusion of the 40 mg/kg dose but also after infusion of saline 
(Fig. II Data Supplement), excluding apoC-III changes as explanation of the rise in TG. Further 
studies are needed to address this question. 
In our previous cynomolgus study (9) infusion of 100 mg/kg of MDCO-216 resulted in a 
drastic shift of apoE away from HDL towards the VLDL and LDL fractions in parallel with a 
several-fold increase of FC and PL in these fractions, suggesting the formation of new FC-PL-
apoE-rich particles with low density. In the present study infusion of 40 mg/kg caused a 
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doubling of FC and PL in VLDL at 8 h (Data Supplement Table III) but only a minor increase 
increase of apoE in the VLDL region and a decrease of apoE in the LDL region, not suggestive 
of formation of such new particles. 
 
General conclusions 
As reported in our previous paper (10) infusion of MDCO-216 caused clear increases in 
plasma PL and TG but non-significant changes in TC. We now report that the infusion causes 
rapid increases of FC but unchanged or at higher doses even decreased CE.  The FC rise was 
non-linear with respect to dose, suggesting that the capacity to handle the influx of FC from 
tissues to plasma is saturating a doses of doses of >= 30 mg/kg.  
MDCO-216 infusion caused complex changes in plasma and lipoprotein lipids, with some of 
the responses still visible  at 168 h after infusion. These late effects cannot be explained by 
the increased cholesterol efflux capacities reported in our previous paper (10), because 
these had returned to baseline by 24 h after infusion.  
Changes in lipid content in the HDL, LDL and VLDL fractions seen by FPLC are generally 
consistent with the  effects on particle concentrations and/or sizes assessed by 1H-NMR. 
The changes in lipoprotein lipids after the 30 and 40 mg/kg doses were in the direction of a 
more “atherogenic” profile (increase in LDL-cholesterol, apoB and LDL particle number, 
increase in plasma and VLDL-TG, decrease in HDL-cholesterol and HDL-particle number) and 
were sustained over a considerable length of time. However, similar lipoprotein profiles are 
observed in carriers of the apoA-IMilano mutation, which do not seem to have more 
manifest heart disease than related subjects not carrying the mutation (2).  We emphasize 
that these changes are much less prominent at doses below 30 mg/kg, whereas the 3-4 fold 
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increases in total and ABCA1-mediated cholesterol efflux capacities are already close to 
maximum at the 20 mg/kg dose (10). 
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FIGURE LEGENDS 
Fig. 1: Effect of increasing doses of MDCO-216 on plasma free cholesterol (top panels) and 
esterified cholesterol (bottom panels) in healthy volunteers (left panels) and CAD patients 
(right panels), expressed as absolute change from baseline. Error bars are SEM for n=4. 
Absolute baseline values for free cholesterol were between 1.01 and 1.18 mM in healthy 
volunteers and between 0.94 and 1.24 mM in CAD patients. For esterified cholesterol they 
were between 3.04 and 3.48 mM in healthy volunteers and between 2.65 and 3.77 mM in 
CAD patient.  *P<0.05 vs 0h (baseline), # P<0.05 vs placebo at the same time-point. 
 
Fig. 2. Effect of increasing doses of MDCO-216 on endogenous plasma cholesterol 
esterification rates in healthy volunteers (left panel) and CAD patients (right panel), 
expressed as absolute change from baseline. Error bars are SEM. Baseline values are 
between 29 and 36 nmoles/ml/h for healthy volunteers and between 35 and 48 
nmoles/ml/h for CAD patients. *P<0.05 vs 0h (baseline). 
 
Fig. 3. Scatterplots showing the relation between the increase of plasma free cholesterol at 8 
h and (A) change in endogenous cholesterol esterification rate at 4 h, (B) change in basal 
efflux from J774 cells at 2 h, and (C) change in SR-B1 mediated efflux from Fu5AH cells at 2 h.  
 
Fig.4. Changes in PL, FC, CE and TG levels in VLDL, LDL and HDL separated by FPLC after 
infusion of 40 mg/kg MDCO-216 in healthy volunteers (left panels) and CAD patients (right 
panels). Error bars represent SEM. *P<0.05 vs 0h (baseline). Absolute values are provided in 
Supplementary Tables II and III.  
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Fig. 5. Distribution of apoE among VLDL, LDL and HDL before and 8 and 24 h after infusion of 
40 mg/kg MDCO-216. Bars represent means + SEM for 8 subjects (4 healthy volunteers and 4 
CAD patients). *: significantly different (p<0.05) from baseline. 
 
Fig. 6. Effect of increasing doses of MDCO-216 on HDL particle concentration and HDL size in 
healthy volunteers (left panels) and CAD patients (right panels), expressed as absolute 
change from baseline. Error bars are SEM. *: significantly different (P<0.05) from zero; #: 
significantly different (p<0.05) from placebo at the same time point.  
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